THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (TOGETHER THIS "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES OF AMERICA, AUSTRALIA, NEW ZEALAND, CANADA, THE REPUBLIC OF SOUTH AFRICA, JAPAN OR ANY OTHER JURISDICTION WHERE, OR TO ANY OTHER PERSON TO WHOM, TO DO SO MIGHT CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW OR REGULATION ("RESTRICTED JURISDICTION"). PLEASE SEE THE IMPORTANT NOTICES AT THE END OF THIS ANNOUNCEMENT.
THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. UPON THE PUBLICATION OF THIS ANNOUNCEMENT THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
17 November 2026
GenIP plc
("GenIP" or the "Company")
Proposed Fundraising, Capital Access Window and Suspension of Trading
GenIP plc (AIM: GNIP), a provider of AI-driven services to help research organisations and corporations commercialise their innovations, announces the utilisation of AIM's Capital Access Window in connection with a proposed equity capital raise (the "Proposed Fundraising").
Proposed Fundraising
The Proposed Fundraising is to support the launch of its Invention Evaluator Platform and to strengthen to Company’s working capital position. The Proposed Fundraising is being conducted by Company’s broker AlbR Capital Limited (“AlbR”) and is not being underwritten.
The timing of its closure, the issue price and allocations are at the discretion of the Company and AlbR.
Investors who meet the required criteria and wish to participate in the Proposed Fundraising should contact AlbR using the details provided below.
A further announcement will be made following completion of the Proposed Fundraising.
Capital Access Window
At the request of the Company, a Capital Access Window will commence at 2.00 p.m. today in accordance with the AIM Rules for Companies.
Accordingly, trading in the Company’s existing ordinary shares on AIM will be temporarily suspended from 2.00 p.m. today while the Proposed Fundraising is conducted.
The Capital Access Window is intended to provide an orderly period in which the Company and its advisers can conduct the proposed Fundraising and determine the appropriate issue price and allocation of new ordinary shares without trading in the Company’s existing ordinary shares taking place concurrently.
During the Capital Access Window, shareholders and other investors will not be able to trade the Company’s ordinary shares on AIM. The suspension is procedural and has been requested by the Company solely in connection with the Proposed Fundraising.
The Company expects to announce the outcome of the Proposed Fundraising, the principal terms of the Proposed Fundraise and the proposed timing for restoration of trading following closure of the Capital Access Window.
The Directors of the Company take responsibility for this announcement.
This announcement does not constitute an offer of securities in any jurisdiction. The Proposed Fundraise, if implemented, will be the subject of further announcements, which will include the material terms and conditions of the Proposed Fundraise.
GenIP plc Melissa Cruz, CEO | Via Walbrook PR |
Beaumont Cornish Limited (Nominated Adviser) Roland Cornish / Asia Szusciak / Andrew Price | Tel: +44 (0) 20 7628 3396 |
AlbR Capital Limited (Joint Broker) Colin Rowbury / Jon Belliss | Tel: +44 (0) 20 7399 9427 cr@albrcapital.com / Jb@albrcapital.com |
Walbrook PR (Financial PR) Alice Woodings William Turner | GenIP@walbrookpr.com Tel: +44 (0) 7407 804 654 Tel: +44 (0) 7407 020 470 |
focusIR (Investor Relations) Kat Perez Dr Paul Cornelius | GenIP@focusIR.com Tel: +44 (0) 20 4570 2234 Tel: +44 (0) 20 4570 2246 |
Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.
Distribution: This announcement has been notified via a Regulatory Information Service and it is not authorised for distribution into North America or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of that jurisdiction.
About GenIP
GenIP is a next-generation business at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.
Service Offerings
GenIP operates through two synergistic service lines:
Service | Description | Value Proposition |
Invention Intelligence Product Suite | AI-powered market intelligence reports assessing the commercial potential of emerging technologies | Enables faster, evidence-based decisions on R&D prioritisation, investment, and IP strategy |
IP Commercialisation Services | End-to-end engagement to help research organisations commercialise innovations | Provides cost-effective, broad support to achieve our clients' strategic objectives |
Together, these services form a unified GenAI-enabled platform for innovation triage and execution.
Vision & Strategy
GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:
- Organic Expansion: Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.
- Service Deepening: Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.
- Strategic Acquisitions: Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
